{
    "clinical_study": {
        "@rank": "153208", 
        "arm_group": [
            {
                "arm_group_label": "Arm I", 
                "arm_group_type": "Experimental", 
                "description": "Patients who didn't have CIA receive oral toremifene daily. Treatment continues for 5 years in the absence of disease progression or unacceptable toxicity"
            }, 
            {
                "arm_group_label": "Arm II", 
                "arm_group_type": "Experimental", 
                "description": "Patients who had CIA receive toremifene as in arm I"
            }, 
            {
                "arm_group_label": "Arm III", 
                "arm_group_type": "Experimental", 
                "description": "Patients without CIA receive oral toremifene and goserelin for ovarian function suppression"
            }, 
            {
                "arm_group_label": "Arm IV", 
                "arm_group_type": "Experimental", 
                "description": "Patients with CIA receive oral toremifene and goserelin for ovarian function suppression."
            }
        ], 
        "brief_summary": {
            "textblock": "Compare the potential benefits of adjuvant toremifene with or without goserelin in\n      premenopausal women with stage I-IIIA, hormonal receptor positive breast cancer accompanied\n      with or without chemotherapy induced amenorrhoea."
        }, 
        "brief_title": "Adjuvant Toremifene With or Without Goserrelin in Premenopausal Women With Stage I-IIIA, Hormonal Receptor Positive Breast Cancer Accompanied With or Without Chemotherapy Induced Amenorrhoea", 
        "condition": [
            "Breast Cancer", 
            "Chemotherapy Induced Amenorrhea", 
            "Ovarian Function Suppression"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Amenorrhea", 
                "Breast Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a single center, randomized, controlled study. Patients undergo surgical resection\n      with standard Doxorubicin/Cyclophosphamide Followed by Docetaxel (AC-T).\n\n      Chemotherapy begins within 4 weeks after surgery for patients randomized to arm I-IV. Arm I:\n      patients who didn't have CIA receive oral toremifene daily. Treatment continues for 5 years\n      in the absence of disease progression or unacceptable toxicity. Arm II: patients who had CIA\n      receive toremifene as in arm I. Arm III: patients without CIA receive oral toremifene and\n      goserelin for ovarian function suppression. Arm IV: patients with CIA receive oral\n      toremifene and goserelin for ovarian function suppression. Patients are followed every 6\n      months for 5 years and annually thereafter."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Written informed consent must be obtained and documented according to the local\n             regulatory requirements prior to beginning specific protocol procedures\n\n          -  Age of at least 18 and at most 45 years\n\n          -  Spontaneous and regular menstrual periods before study entry with FSH below 15 mlU/ml\n             in follicular phase\n\n          -  Histologically confirmed primary breast cancer with the need for anthracycline-based\n             chemotherapy\n\n          -  Steroid receptor (estrogen and progesterone) positive tumor (diagnosis according to\n             hospital standard-procedures)\n\n          -  No clinical evidence of local recurrence or distant metastases. Complete staging\n             work-up within 3 months prior to registration. All patients must have (bilateral)\n             mammography or breast MRI, chest X-ray; other tests may be performed as clinically\n             indicated\n\n          -  Karnofsky-Index >80%\n\n          -  Life expectancy of at least 10 years, disregarding the diagnosis of cancer\n\n          -  Adequate organ function including normal red and white blood count, platelets, serum\n             creatinine, bilirubin, and transaminases within normal range of the institution\n\n          -  Patients underwent standard Doxorubicin/Cyclophosphamide Followed by Docetaxel (AC-T)\n\n          -  Patients must be available for and compliant to treatment and follow-up. Patients\n             registered on this trial must be treated and followed up at the participating center.\n\n        Exclusion Criteria:\n\n          -  Known hypersensitivity reaction to the investigational compounds or incorporated\n             substances\n\n          -  Prior cytotoxic treatment for any reason\n\n          -  Suspected (primary or secondary) ovarian insufficiency\n\n          -  Pregnant or lactating patients. Patients of childbearing potential must have a\n             negative pregnancy test (urine or serum) within 14 days prior to registration and\n             must implement adequate non-hormonal contraceptive measures during study treatment;\n             prior use of hormonal contraceptives has to be discontinued before first Goserelin\n             injection\n\n          -  Other serious illness or medical condition that may interfere with the understanding\n             and giving of informed consent and the conduct of the study\n\n          -  Prior or concomitant secondary malignancy (except non-melanomatous skin cancer or\n             carcinoma in situ of the uterine cervix)\n\n          -  Concurrent treatment with other experimental drugs or any other anti-cancer therapy\n\n          -  Concurrent treatment with sex hormones. Prior treatment must be stopped before study\n             entry"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 5, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02132390", 
            "org_study_id": "PUMCH-Breast-CIA"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Arm III", 
                    "Arm IV"
                ], 
                "intervention_name": "Goserelin", 
                "intervention_type": "Drug", 
                "other_name": "Zoladex"
            }, 
            {
                "arm_group_label": [
                    "Arm I", 
                    "Arm II"
                ], 
                "intervention_name": "Toremifene", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Toremifene", 
                "Goserelin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Breast cancer", 
            "Chemotherapy induced amenorrhea", 
            "Goserelin"
        ], 
        "lastchanged_date": "June 2, 2014", 
        "location": {
            "contact": {
                "email": "wcj_sumy@126.com", 
                "last_name": "Yidong ZHOU, Master", 
                "phone": "8610-69152700"
            }, 
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "state": "Beijing", 
                    "zip": "100730"
                }, 
                "name": "Peking Union Medical College Hospital"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "4", 
        "official_title": "Study of Adjuvant Toremifene With or Without Goserrelin in Premenopausal Women With Stage I-IIIA, Hormonal Receptor Positive Breast Cancer Accompanied With or Without Chemotherapy Induced Amenorrhoea", 
        "overall_contact": {
            "email": "wcj_sumy@126.com", 
            "last_name": "Yidong ZHOU, Master", 
            "phone": "0086-10-69152700"
        }, 
        "overall_contact_backup": {
            "last_name": "Changjun WANG, Doctor", 
            "phone": "0086-10-69152700"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "May 2024", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Disease free survival", 
                "safety_issue": "No", 
                "time_frame": "up to 120 months"
            }, 
            {
                "measure": "Overall Survival", 
                "safety_issue": "No", 
                "time_frame": "up to 120 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02132390"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Peking Union Medical College Hospital", 
            "investigator_full_name": "ZHOU Yidong", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Quality of life", 
                "safety_issue": "No", 
                "time_frame": "up to 120 months"
            }, 
            {
                "description": "measured by dual energy X-ray absorptiometry scans at every 12 months and by serum biomarkers", 
                "measure": "Bone mineral density loss", 
                "safety_issue": "No", 
                "time_frame": "up to 120 months"
            }, 
            {
                "measure": "Hormone levels", 
                "safety_issue": "No", 
                "time_frame": "up to 120 months"
            }, 
            {
                "measure": "Incidence of pregnancy", 
                "safety_issue": "No", 
                "time_frame": "up to 120 months"
            }
        ], 
        "source": "Peking Union Medical College Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Peking Union Medical College Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}